BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. AIDS. 1997;11:107-112. [PMID: 9110083 DOI: 10.1097/00002030-199701000-00016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Reuter A, Seddon JA, Marais BJ, Furin J. Preventing tuberculosis in children: A global health emergency. Paediatr Respir Rev 2020;36:44-51. [PMID: 32253128 DOI: 10.1016/j.prrv.2020.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Prado TN, Rajan JV, Miranda AE, Dias ED, Cosme LB, Possuelo LG, Sanchez MN, Golub JE, Riley LW, Maciel EL. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis. Braz J Infect Dis 2017;21:162-70. [PMID: 27936379 DOI: 10.1016/j.bjid.2016.11.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
3 Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J 2014;17:26. [PMID: 24932337 DOI: 10.11604/pamj.2014.17.26.2641] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wingfield T, Tovar MA, Huff D, Boccia D, Montoya R, Ramos E, Datta S, Saunders MJ, Lewis JJ, Gilman RH, Evans CA. A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru. Bull World Health Organ 2017;95:270-80. [PMID: 28479622 DOI: 10.2471/BLT.16.170167] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
5 Watson DC, Collins-Jones TL, Lovelace S. Antiretroviral therapy of pediatric HIV infection: making hope a reality. AIDS Patient Care STDS 1999;13:587-99. [PMID: 19555271 DOI: 10.1089/apc.1999.13.587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Kittikraisak W, Burapat C, Kaewsa-ard S, Watthanaamornkiet W, Sirinak C, Sattayawuthipong W, Jittimanee S, Pobkeeree V, Varma JK. Factors associated with tuberculosis treatment default among HIV-infected tuberculosis patients in Thailand. Trans R Soc Trop Med Hyg 2009;103:59-66. [PMID: 18937958 DOI: 10.1016/j.trstmh.2008.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
7 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Edessa D, Sisay M, Dessie Y. Unfavorable outcomes to second-line tuberculosis therapy among HIV-infected versus HIV-uninfected patients in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One 2020;15:e0237534. [PMID: 32797110 DOI: 10.1371/journal.pone.0237534] [Reference Citation Analysis]
9 Aquino DS, Moura LC, Maruza M, Silva AP, Ximenes RA, Lacerda HR, Miranda Filho Dde B, Albuquerque Mde F. Factors associated with treatment for latent tuberculosis in persons living with HIV/AIDS. Cad Saude Publica 2015;31:2505-13. [PMID: 26872227 DOI: 10.1590/0102-311X00154614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Oni T, Tsekela R, Kwaza B, Manjezi L, Bangani N, Wilkinson KA, Coetzee D, Wilkinson RJ. A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town. PLoS One 2012;7:e52489. [PMID: 23285064 DOI: 10.1371/journal.pone.0052489] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
11 Tornheim JA, Lozano Beltran DF, Gilman RH, Castellon M, Solano Mercado MA, Sullca W, Torrico F, Bern C. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl Trop Dis 2013;7:e2407. [PMID: 24069472 DOI: 10.1371/journal.pntd.0002407] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kilmarx PH, Supawitkul S, Wankrairoj M, Uthaivoravit W, Limpakarnjanarat K, Saisorn S, Mastro TD. Explosive spread and effective control of human immunodeficiency virus in northernmost Thailand: the epidemic in Chiang Rai province, 1988–99: . AIDS 2000;14:2731-40. [DOI: 10.1097/00002030-200012010-00013] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
13 Danyuttapolchai J, Kittimunkong S, Nateniyom S, Painujit S, Klinbuayaem V, Maipanich N, Maokamnerd Y, Pevzner E, Whitehead S, Kanphukiew A, Monkongdee P, Martin M. Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. PLoS One 2017;12:e0184986. [PMID: 28949995 DOI: 10.1371/journal.pone.0184986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
14 Colebunders R, Verdonck K, Nachega J, Kothari P. Impact of New Developments in Antiretroviral Treatment on AIDS Prevention and Care in Resource-Poor Countries. AIDS Patient Care and STDs 2000;14:251-7. [DOI: 10.1089/108729100317713] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
15 Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study. BMC Infect Dis 2020;20:294. [PMID: 32664847 DOI: 10.1186/s12879-020-05011-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Hovell MF, Sipan CL, Blumberg EJ, Hofstetter CR, Slymen D, Friedman L, Moser K, Kelley NJ, Vera AY. Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial. Am J Public Health 2003;93:1871-7. [PMID: 14600055 DOI: 10.2105/ajph.93.11.1871] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
17 Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. PLoS One 2014;9:e87166. [PMID: 24498298 DOI: 10.1371/journal.pone.0087166] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
18 Crampin A, Kasimba S, Mwaungulu NJ, Dacombe R, Floyd S, Glynn JR, Fine PE. Married to M. tuberculosis: risk of infection and disease in spouses of smear-positive tuberculosis patients. Trop Med Int Health 2011;16:811-8. [PMID: 21447058 DOI: 10.1111/j.1365-3156.2011.02763.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
19 Rutherford ME, Ruslami R, Maharani W, Yulita I, Lovell S, Van Crevel R, Alisjahbana B, Hill PC. Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Res Notes 2012;5:7. [PMID: 22221424 DOI: 10.1186/1756-0500-5-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
20 Schluger NW, Burzynski J. Tuberculosis and HIV infection: epidemiology, immunology, and treatment. HIV Clin Trials 2001;2:356-65. [PMID: 11590540 DOI: 10.1310/TUNH-UAKU-N0E4-1PXF] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi SV. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care 2017;29:936-42. [PMID: 28147705 DOI: 10.1080/09540121.2017.1283390] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
22 Palwatwichai A. Tuberculosis in Thailand. Respirology 2001;6:65-70. [PMID: 11264766 DOI: 10.1046/j.1440-1843.2001.00299.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
23 Berhe M, Demissie M, Tesfaye G. Isoniazid Preventive Therapy Adherence and Associated Factors among HIV Positive Patients in Addis Ababa, Ethiopia. Advances in Epidemiology 2014;2014:1-6. [DOI: 10.1155/2014/230587] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
24 Boffa J, Mayan M, Ndlovu S, Fisher D, Staples S, Sauve R, Williamson T. When prevention is dangerous: perceptions of isoniazid preventive therapy in KwaZulu-Natal, South Africa. Public Health Action 2019;9:24-31. [PMID: 30963039 DOI: 10.5588/pha.18.0040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 LaCourse SM, Deya RW, Graham SM, Masese LN, Jaoko W, Mandaliya KN, Overbaugh J, McClelland RS. Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 2017;76:74-81. [PMID: 28797022 DOI: 10.1097/QAI.0000000000001461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Marais BJ, Ayles H, Graham SM, Godfrey-faussett P. Screening and Preventive Therapy for Tuberculosis. Clinics in Chest Medicine 2009;30:827-46. [DOI: 10.1016/j.ccm.2009.08.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
27 Ayele AA, Asrade Atnafie S, Balcha DD, Weredekal AT, Woldegiorgis BA, Wotte MM, Gebresillasie BM. Self-reported adherence and associated factors to isoniazid preventive therapy for latent tuberculosis among people living with HIV/AIDS at health centers in Gondar town, North West Ethiopia. Patient Prefer Adherence 2017;11:743-9. [PMID: 28435232 DOI: 10.2147/PPA.S131314] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
28 Sarcletti M, Zangerle R. Persistent Flank Pain, Low-Grade Fever, and Malaise in a Woman Treated with Indinavir. AIDS Patient Care and STDs 1999;13:81-7. [DOI: 10.1089/apc.1999.13.81] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
29 Perlman DC, Gourevitch MN, Trinh C, Salomon N, Horn L, Des Jarlais DC. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. J Urban Health 2001;78:550-67. [PMID: 11564856 DOI: 10.1093/jurban/78.3.550] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV Protease Inhibitors with ATP-Dependent Drug Export Proteins. Mol Pharmacol 1999;56:383-9. [DOI: 10.1124/mol.56.2.383] [Cited by in Crossref: 138] [Cited by in F6Publishing: 129] [Article Influence: 6.3] [Reference Citation Analysis]
31 Nelson K. Tuberculin testing to detect latent tuberculosis in developing countries. Epidemiology 2007;18:348-9. [PMID: 17435443 DOI: 10.1097/01.ede.0000259985.76928.64] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
32 Murray CJ, Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A 1998;95:13881-6. [PMID: 9811895 DOI: 10.1073/pnas.95.23.13881] [Cited by in Crossref: 155] [Cited by in F6Publishing: 122] [Article Influence: 6.7] [Reference Citation Analysis]
33 Feingold AR, Rutstein RM, Meislich D, Brown T, Rudy BJ. Protease inhibitor therapy in HIV-infected children. AIDS Patient Care STDS 2000;14:589-93. [PMID: 11155900 DOI: 10.1089/10872910050193761] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
34 van Griensven J, Choun K, Chim B, Thai S, Lorent N, Lynen L. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. Trop Med Int Health 2015;20:1823-31. [PMID: 26426387 DOI: 10.1111/tmi.12609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
35 Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007;4:e238. [PMID: 17676945 DOI: 10.1371/journal.pmed.0040238] [Cited by in Crossref: 482] [Cited by in F6Publishing: 384] [Article Influence: 34.4] [Reference Citation Analysis]
36 Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health 2010;10:651. [PMID: 21029405 DOI: 10.1186/1471-2458-10-651] [Cited by in Crossref: 82] [Cited by in F6Publishing: 69] [Article Influence: 7.5] [Reference Citation Analysis]
37 Piyaworawong S, Yanai H, Nedsuwan S, Akarasewi P, Moolphate S, Sawanpanyalert P. Tuberculosis preventative therapy as part of a care package for people living with HIV in a district of Thailand: . AIDS 2001;15:1739-41. [DOI: 10.1097/00002030-200109070-00022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
38 Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, McCarthy AE. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis 2006;6:97. [PMID: 16772037 DOI: 10.1186/1471-2334-6-97] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
39 Akamike IC, Okedo-Alex IN, Agu AP, Alo C, Ogbonnaya LU. Knowledge and adherence to isoniazid preventive therapy among people living with HIV in multilevel health facilities in South-East, Nigeria: baseline findings from a quasi-experimental study. Pan Afr Med J 2020;36:261. [PMID: 33014257 DOI: 10.11604/pamj.2020.36.261.22496] [Reference Citation Analysis]
40 Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, Samandari T. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One 2011;6:e18435. [PMID: 21541021 DOI: 10.1371/journal.pone.0018435] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]